- €3.45bn
- €4.02bn
- €1.20bn
Italy's DiaSorin cautions on supply chain, logistics risks as it sets 2026 targets
Brief: Diasorin FY Adjusted EBITDA EUR 394 Mln
Italy - Factors to watch on March 20
Brief: Diasorin Submits LIAISON NES Group A Strep Molecular Test To The U.S. FDA For 510(K) Clearance And CLIA Waiver
Brief: Diasorin Receives Approval For HDV Laboratory Test In The U.S.
Italy - Factors to watch on January 26
Brief: Diasorin Appoints Alberto Donati As Group CFO
Live Markets: Is Medtech ready to turn the corner?
DiaSorin rises as FDA okays new molecular diagnostic platform
Italy - Factors to watch on December 23
Brief: Diasorin Board Proposes Buyback Up To EUR 250 Mln
Europe Research Roundup: Beiersdorf, Neste, RS Group
Live Markets: Before the bell: futures steady, focus on Bayer, STOXX reshuffle
Fincantieri seen joining FTSE MIB as defence stocks surge, ousting Hera or DiaSorin
Deutsche Bank cuts Italy's DiaSorin to 'hold' on 'notable' growth slowdown
Live Markets: STOXX dips, Legrand weighs on AI plays, UK banks up
DiaSorin shares hit over 8-yr lows on Q3 miss, guidance cut
Europe Research Roundup: Applied Nutrition, Noba Bank Group, Trainline
Brief: Diasorin Q3 Net Profit EUR 38 Mln